Base de dados : MEDLINE
Pesquisa : Z01.107.424 [Categoria DeCS]
Referências encontradas : 9626 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 963 ir para página                         

  1 / 9626 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Registro de Ensaios Clínicos
Texto completo
[PMID]:28455172
[Au] Autor:Lopez-Medina E; Melgar M; Gaensbauer JT; Bandyopadhyay AS; Borate BR; Weldon WC; Rüttimann R; Ward J; Clemens R; Asturias EJ
[Ad] Endereço:Department of Pediatrics, Universidad del Valle and Centro de Estudios en Infectología Pediátrica, Cali, Colombia.
[Ti] Título:Inactivated polio vaccines from three different manufacturers have equivalent safety and immunogenicity when given as 1 or 2 additional doses after bivalent OPV: Results from a randomized controlled trial in Latin America.
[So] Source:Vaccine;35(28):3591-3597, 2017 06 16.
[Is] ISSN:1873-2518
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Since April 2016 inactivated poliovirus vaccine (IPV) has been the only routine source of polio type 2 protection worldwide. With IPV supply constraints, data on comparability of immunogenicity and safety will be important to optimally utilize available supplies from different manufacturers. METHODS: In this multicenter phase IV study, 900 Latin American infants randomly assigned to six study groups received three doses of bOPV at 6, 10 and 14weeks and either one IPV dose at 14weeks (groups SP-1, GSK-1 and BBio-1) or two IPV doses at 14 and 36weeks (groups SP-2, GSK-2 and BBio-2) from three different manufacturers. Children were challenged with mOPV2 at either 18 (one IPV dose) or 40weeks (two IPV doses) and stools were collected weekly for 4weeks to assess viral shedding. Serum neutralizing antibodies were measured at various time points pre and post vaccination. Serious adverse events and important medical events (SAE and IME) were monitored for 6months after last study vaccine. RESULTS: At week 18, 4weeks after one dose of IPV, overall type 2 seroconversion rates were 80.4%, 80.4% and 73.3% for SP-1, GSK-1 and BBio-1 groups, respectively; and 92.6%, 96.8% and 88.0% in those who were seronegative before IPV administration. At 40weeks, 4weeks after a second IPV dose, type 2 seroconversion rates were ≥99% for any of the three manufacturers. There were no significant differences in fecal shedding index endpoint (SIE) after one or two IPV doses (SP: 2.3 [95% CI: 2.1-2.6]); GSK: 2.2 [1.7-2.5]; BBio 1.8 [1.5-2.3]. All vaccines appeared safe, with no vaccine-related SAE or IME. CONCLUSION: Current WHO prequalified IPV vaccines are safe and induce similar humoral and intestinal immunity after one or two doses. The parent study was registered with ClinicalTrials.gov, number NCT01831050.
[Mh] Termos MeSH primário: Esquemas de Imunização
Imunogenicidade da Vacina
Vacina Antipólio de Vírus Inativado/efeitos adversos
Vacina Antipólio de Vírus Inativado/imunologia
[Mh] Termos MeSH secundário: Anticorpos Neutralizantes/sangue
Anticorpos Neutralizantes/imunologia
Anticorpos Antivirais/sangue
Anticorpos Antivirais/imunologia
Fezes/virologia
Feminino
Seres Humanos
Imunidade Humoral
Lactente
Intestinos/imunologia
América Latina
Masculino
Poliomielite/prevenção & controle
Vacina Antipólio de Vírus Inativado/administração & dosagem
Vacina Antipólio Oral/administração & dosagem
Vacina Antipólio Oral/efeitos adversos
Vacina Antipólio Oral/imunologia
Soroconversão
Vacinação
Eliminação de Partículas Virais
Organização Mundial da Saúde
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE IV; JOURNAL ARTICLE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antibodies, Neutralizing); 0 (Antibodies, Viral); 0 (Poliovirus Vaccine, Inactivated); 0 (Poliovirus Vaccine, Oral)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180309
[Lr] Data última revisão:
180309
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170430
[Cl] Clinical Trial:ClinicalTrial
[St] Status:MEDLINE


  2 / 9626 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29293596
[Au] Autor:Ramírez-Hurtado JM; Berbel-Pineda JM; Palacios-Florencio B
[Ad] Endereço:Department of Economics, Quantitative Methods and Economic History, Pablo de Olavide University, Seville, Spain.
[Ti] Título:Study of the influence of socio-economic factors in the international expansion of Spanish franchisors to Latin American countries.
[So] Source:PLoS One;13(1):e0190391, 2018.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The saturation of the domestic market is one of the factors which drive firms to expand their business to other markets. Franchising is one of the formats adopted by companies when establishing their internationalization strategy. Spain is a country where franchising is strongly consolidated. This degree of maturity means that many chains seek other countries in which to operate. This work's specific aims are, on the one hand, to offer a general view of the current situation of Spanish franchisors in Latin American countries and, on the other hand, to analyze which the socio-economic or external factors are that determine the presence of Spanish franchisors in this market. Canonical-correlation analysis is used to do so. The results show that Spanish franchisors focus on the market's potential and size, and the per capita income, while they do not take into account its unemployment level, the country risk or the competitiveness there. This work shows that there is a series of socio-economic factors which influence the final choice of the destination country. However, this decision is not solely based on this country's socio-economic aspects, but also on the structure of the franchising firm itself and on its export experience in other markets. This study therefore complements other research and helps franchisors in their difficult decision of choosing the destination for their internationalization.
[Mh] Termos MeSH primário: Internacionalidade
Fatores Socioeconômicos
[Mh] Termos MeSH secundário: Seres Humanos
América Latina
Espanha
Desemprego
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180221
[Lr] Data última revisão:
180221
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180103
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0190391


  3 / 9626 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28466545
[Au] Autor:Corrêa de Araujo Koury L; Ganser A; Berliner N; Rego EM
[Ad] Endereço:Department of Internal Medicine, Medical School of Ribeirão Preto, and Centre for Cell-Based Therapy, University of São Paulo, Ribeirao Preto, SP, Brazil.
[Ti] Título:Treating acute promyelocytic leukaemia in Latin America: lessons from the International Consortium on Acute Leukaemia experience.
[So] Source:Br J Haematol;177(6):979-983, 2017 06.
[Is] ISSN:1365-2141
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:The Latin Americas and Caribbean are regions where social exclusion and inequality persist as the main obstacles to human development and improvement of health conditions, despite economic growth and social development. These countries need to establish international collaborations with the goal of improving health conditions. In this scenario Acute Promyelocytic Leukaemia (APL), a disease with a high cure rate in developed countries and high prevalence in young patients, offers an ideal opportunity to implement measures with educational and cooperative scope. We discuss the experience of Latin America and the Caribbean through a common network, the International Consortium on Acute Promyelocytic Leukaemia (IC-APL).
[Mh] Termos MeSH primário: Antineoplásicos/uso terapêutico
Cooperação Internacional
Leucemia Promielocítica Aguda/tratamento farmacológico
[Mh] Termos MeSH secundário: Países em Desenvolvimento
Seres Humanos
América Latina
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antineoplastic Agents)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:180209
[Lr] Data última revisão:
180209
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170504
[St] Status:MEDLINE
[do] DOI:10.1111/bjh.14589


  4 / 9626 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28460996
[Au] Autor:Rosado-García FM; Guerrero-Flórez M; Karanis G; Hinojosa MDC; Karanis P
[Ad] Endereço:State Key Laboratory of Plateau Ecology and Agriculture, Center for Biomedicine and Infectious Diseases, Qinghai Academy of Animal Science and Veterinary Medicine, Qinghai University, Xining, Qinghai, PR China; National Institute of Hygiene, Epidemiology and Microbiology of Cuba, Cuba.
[Ti] Título:Water-borne protozoa parasites: The Latin American perspective.
[So] Source:Int J Hyg Environ Health;220(5):783-798, 2017 07.
[Is] ISSN:1618-131X
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:Health systems, sanitation and water access have certain limitations in nations of Latin America (LA): typical matters of developing countries. Water is often contaminated and therefore unhealthy for the consumers and users. Information on prevalence and detection of waterborne parasitic protozoa are limited or not available in LA. Only few reports have documented in this field during the last forty years and Brazil leads the list, including countries in South America and Mexico within Central America region and Caribbean islands. From 1979 to 2015, 16 outbreaks of waterborne-protozoa, were reported in Latin American countries. T. gondii and C. cayetanensis were the protozoa, which caused more outbreaks and Giardia spp. and Cryptosporidium spp. were the most frequently found protozoa in water samples. On the other hand, Latin America countries have not got a coherent methodology for detection of protozoa in water samples despite whole LA is highly vulnerable to extreme weather events related to waterborne-infections; although Brazil and Colombia have some implemented laws in their surveillance systems. It would be important to coordinate all surveillance systems in between all countries for early detection and measures against waterborne-protozoan and to establish effective and suitable diagnosis tools according to the country's economic strength and particular needs.
[Mh] Termos MeSH primário: Parasitos/isolamento & purificação
Microbiologia da Água
Poluentes da Água/isolamento & purificação
[Mh] Termos MeSH secundário: Animais
Mudança Climática
Monitoramento Ambiental
Seres Humanos
América Latina
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Water Pollutants)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:180206
[Lr] Data última revisão:
180206
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170503
[St] Status:MEDLINE


  5 / 9626 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28449318
[Au] Autor:Zammarchi L; Bonati M; Strohmeyer M; Albonico M; Requena-Méndez A; Bisoffi Z; Nicoletti A; García HH; Bartoloni A; COHEMI Project Study Group
[Ad] Endereço:Unità di Malattie Infettive, Università Degli Studi di Firenze, Florence, Italy.
[Ti] Título:Screening, diagnosis and management of human cysticercosis and Taenia solium taeniasis: technical recommendations by the COHEMI project study group.
[So] Source:Trop Med Int Health;22(7):881-894, 2017 07.
[Is] ISSN:1365-3156
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Neurocysticercosis, the central nervous system's localised form of cysticercosis, is considered to be the leading cause of epilepsy in the developing world. In Europe, the disease is mainly imported and affects both immigrants and travellers. However, autochthonous cases of cysticercosis in low-endemic countries could also originate from Taenia solium carriers (migrants or travellers) who acquired taeniasis overseas. Management of cysticercosis is a challenge for European healthcare providers as they are often hardly aware of this infection and have little familiarity in managing this disease. This study provides a summary of recommendations concerning screening, diagnosis and management of cysticercosis and T. solium taeniasis in Europe drawn up by nine experts in migrant health and imported diseases with experience in cysticercosis and T. solium taeniasis.
[Mh] Termos MeSH primário: Antiparasitários/uso terapêutico
Cisticercose/diagnóstico
Cisticercose/tratamento farmacológico
Taenia solium/isolamento & purificação
[Mh] Termos MeSH secundário: Animais
Europa (Continente)
Seres Humanos
América Latina
Migrantes
[Pt] Tipo de publicação:JOURNAL ARTICLE; PRACTICE GUIDELINE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antiparasitic Agents)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:180129
[Lr] Data última revisão:
180129
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170428
[St] Status:MEDLINE
[do] DOI:10.1111/tmi.12887


  6 / 9626 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29261739
[Au] Autor:Elgart JF; Prestes M; Gonzalez L; Rucci E; Gagliardino JJ; QUALIDIAB Net study group
[Ad] Endereço:CENEXA. Center of Experimental and Applied Endocrinology (UNLP-CONICET La Plata), School of Medicine, National University of La Plata, La Plata, Argentina.
[Ti] Título:Relation between cost of drug treatment and body mass index in people with type 2 diabetes in Latin America.
[So] Source:PLoS One;12(12):e0189755, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:AIMS: Despite the frequent association of obesity with type 2 diabetes (T2D), the effect of the former on the cost of drug treatment of the latest has not been specifically addressed. We studied the association of overweight/obesity on the cost of drug treatment of hyperglycemia, hypertension and dyslipidemia in a population with T2D. METHODS: This observational study utilized data from the QUALIDIAB database on 3,099 T2D patients seen in Diabetes Centers in Argentina, Chile, Colombia, Peru, and Venezuela. Data were grouped according to body mass index (BMI) as Normal (18.5≤BMI<25), Overweight (25≤BMI<30), and Obese (BMI≥30). Thereafter, we assessed clinical and metabolic data and cost of drug treatment in each category. Statistical analyses included group comparisons for continuous variables (parametric or non-parametric tests), Chi-square tests for differences between proportions, and multivariable regression analysis to assess the association between BMI and monthly cost of drug treatment. RESULTS: Although all groups showed comparable degree of glycometabolic control (FBG, HbA1c), we found significant differences in other metabolic control indicators. Total cost of drug treatment of hyperglycemia and associated cardiovascular risk factors (CVRF) increased significantly (p<0.001) with increment of BMI. Hyperglycemia treatment cost showed a significant increase concordant with BMI whereas hypertension and dyslipidemia did not. Despite different values and percentages of increase, this growing cost profile was reproduced in every participating country. BMI significantly and independently affected hyperglycemia treatment cost. CONCLUSIONS: Our study shows for the first time that BMI significantly increases total expenditure on drugs for T2D and its associated CVRF treatment in Latin America.
[Mh] Termos MeSH primário: Índice de Massa Corporal
Custos e Análise de Custo
Diabetes Mellitus Tipo 2/tratamento farmacológico
Diabetes Mellitus Tipo 2/economia
Hipoglicemiantes/economia
Hipoglicemiantes/uso terapêutico
[Mh] Termos MeSH secundário: Feminino
Seres Humanos
Hiperglicemia/tratamento farmacológico
Hiperglicemia/economia
América Latina
Masculino
Meia-Idade
Análise Multivariada
Análise de Regressão
Fatores de Risco
[Pt] Tipo de publicação:JOURNAL ARTICLE; OBSERVATIONAL STUDY
[Nm] Nome de substância:
0 (Hypoglycemic Agents)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180108
[Lr] Data última revisão:
180108
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171221
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0189755


  7 / 9626 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28453508
[Au] Autor:Lambertini M; Goldrat O; Barragan-Carrillo R; Viglietti G; Demeestere I; Villarreal-Garza C
[Ad] Endereço:Breast Cancer Translational Research Laboratory, Department of Medicine, Institut Jules Bordet and l'Université Libre de Bruxelles (ULB), Brussels, Belgium.
[Ti] Título:Viable Options for Fertility Preservation in Breast Cancer Patients: A Focus on Latin America.
[So] Source:Rev Invest Clin;69(2):103-113, 2017 Mar-Apr.
[Is] ISSN:0034-8376
[Cp] País de publicação:Mexico
[La] Idioma:eng
[Ab] Resumo:Thanks to the improved survival outcomes observed in recent years, a growing attention has been given to the quality of life issues faced by young women with breast cancer such as fertility preservation and concerns related to future pregnancies. However, several challenges remain for young women with breast cancer considering undergoing fertility preservation strategies. Further specific issues on this regard should be taken into account in Latin America, where patients and physicians face particular barriers that hinder the routine adoption of this practice. Hence, further efforts are needed to overcome these deficiencies and improve the correct referral of breast cancer patients to fertility preservation strategies. The aim of the present review is to focus on the risk of anticancer treatment-related premature ovarian failure and infertility in young breast cancer patients, to summarize the current knowledge on the available options for fertility preservation, and to discuss the safety issues of pregnancy in breast cancer survivors. Furthermore, this review aims to highlight the specific clinical challenges in this field encountered by healthcare providers and young breast cancer patients from Latin American countries.
[Mh] Termos MeSH primário: Neoplasias da Mama/terapia
Preservação da Fertilidade/métodos
Infertilidade Feminina/prevenção & controle
[Mh] Termos MeSH secundário: Adulto
Sobreviventes de Câncer
Feminino
Seres Humanos
Infertilidade Feminina/etiologia
América Latina
Gravidez
Insuficiência Ovariana Primária/etiologia
Qualidade de Vida
Encaminhamento e Consulta
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171220
[Lr] Data última revisão:
171220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170429
[St] Status:MEDLINE


  8 / 9626 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28453507
[Au] Autor:Chavarri-Guerra Y; Blazer KR; Weitzel JN
[Ad] Endereço:Department of Hemato-Oncology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubiran, Mexico City, Mexico.
[Ti] Título:Genetic Cancer Risk Assessment for Breast Cancer in Latin America.
[So] Source:Rev Invest Clin;69(2):94-102, 2017 Mar-Apr.
[Is] ISSN:0034-8376
[Cp] País de publicação:Mexico
[La] Idioma:eng
[Ab] Resumo:In Latin America, breast cancer is the most common malignancy in women, and limited available data suggest that up to 15% of all breast cancer cases in the region are hereditary. Genetic cancer risk assessment and counseling is a critical component of the appropriate clinical care of patients with hereditary breast cancer and their families. Unfortunately, genetic services are underdeveloped across Latin America, and access to genetic testing and counseling is very scarce in the region. Barriers contributing to the access to genetic care are high cost and lack of insurance coverage for genetic tests, insufficient oncogenetics training or expertise, nonexistence of genetic counseling as a clinical discipline, and lack of supportive healthcare policies. In this review, we highlight relevant initiatives undertaken in several Latin American countries aimed at creating genetic cancer risk assessment programs. Additionally, we present a review of the scientific literature on the current status of breast cancer genomics in Latin America, with specific emphasis on demographic indicators, access to cancer genetic care, training and strategies to improve outcomes, and international collaborations.
[Mh] Termos MeSH primário: Neoplasias da Mama/epidemiologia
Aconselhamento Genético/métodos
Testes Genéticos/métodos
[Mh] Termos MeSH secundário: Neoplasias da Mama/diagnóstico
Neoplasias da Mama/genética
Feminino
Predisposição Genética para Doença
Testes Genéticos/economia
Acesso aos Serviços de Saúde
Seres Humanos
Cobertura do Seguro
América Latina/epidemiologia
Medição de Risco/métodos
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171220
[Lr] Data última revisão:
171220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170429
[St] Status:MEDLINE


  9 / 9626 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Colombo, Arnaldo Lopes
Camargo, Zoilo Pires de
Texto completo SciELO Brasil
[PMID]:28746570
[Au] Autor:Shikanai-Yasuda MA; Mendes RP; Colombo AL; Queiroz-Telles F; Kono ASG; Paniago AMM; Nathan A; Valle ACFD; Bagagli E; Benard G; Ferreira MS; Teixeira MM; Silva-Vergara ML; Pereira RM; Cavalcante RS; Hahn R; Durlacher RR; Khoury Z; Camargo ZP; Moretti ML; Martinez R
[Ad] Endereço:Departamento de Moléstias Infecciosas e Parasitárias, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brasil.
[Ti] Título:Brazilian guidelines for the clinical management of paracoccidioidomycosis.
[So] Source:Rev Soc Bras Med Trop;50(5):715-740, 2017 Sep-Oct.
[Is] ISSN:1678-9849
[Cp] País de publicação:Brazil
[La] Idioma:eng
[Ab] Resumo:Paracoccidioidomycosis is a systemic fungal disease occurring in Latin America that is associated with rural environments and agricultural activities. However, the incidence and prevalence of paracoccidiodomycosis is underestimated because of the lack of compulsory notification. If paracoccidiodomycosis is not diagnosed and treated early and adequately, the endemic fungal infection could result in serious sequelae. While the Paracoccidioides brasiliensis ( P. brasiliensis ) complex has been known to be the causal agent of paracoccidiodomycosis, a new species, Paracoccidioides lutzii ( P. lutzii ), has been reported in Rondônia, where the disease has reached epidemic levels, and in the Central West and Pará. Accurate diagnoses and availability of antigens that are reactive with the patients' sera remain significant challenges. Therefore, the present guidelines aims to update the first Brazilian consensus on paracoccidioidomycosis by providing evidence-based recommendations for bedside patient management. This consensus summarizes etiological, ecoepidemiological, molecular epidemiological, and immunopathological data, with emphasis on clinical, microbiological, and serological diagnosis and management of clinical forms and sequelae, as well as in patients with comorbidities and immunosuppression. The consensus also includes discussion of outpatient treatments, severe disease forms, disease prevalence among special populations and resource-poor settings, a brief review of prevention and control measures, current challenges and recommendations.
[Mh] Termos MeSH primário: Antifúngicos/uso terapêutico
Gerenciamento Clínico
Paracoccidioidomicose/tratamento farmacológico
Paracoccidioidomicose/patologia
[Mh] Termos MeSH secundário: Brasil
Consenso
Diagnóstico Diferencial
Seres Humanos
Itraconazol/uso terapêutico
América Latina
Paracoccidioides
[Pt] Tipo de publicação:JOURNAL ARTICLE; PRACTICE GUIDELINE
[Nm] Nome de substância:
0 (Antifungal Agents); 304NUG5GF4 (Itraconazole)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171218
[Lr] Data última revisão:
171218
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170727
[St] Status:MEDLINE


  10 / 9626 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
[PMID]:27775637
[Au] Autor:Wang JN; Ling F
[Ad] Endereço:Zhejiang Provincial Center for Disease Control and Prevention, 3399 Binsheng Road, Hangzhou 310051, China. jnwang@cdc.zj.cn.
[Ti] Título:Zika Virus Infection and Microcephaly: Evidence for a Causal Link.
[So] Source:Int J Environ Res Public Health;13(10), 2016 10 20.
[Is] ISSN:1660-4601
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:Zika virus (ZIKV) is a flavivirus related to the Dengue, yellow fever and West Nile viruses. Since the explosive outbreaks of ZIKV in Latin America in 2015, a sudden increase in the number of microcephaly cases has been observed in infants of women who were pregnant when they contracted the virus. The severity of this condition raises grave concerns, and extensive studies on the possible link between ZIKV infection and microcephaly have been conducted. There is substantial evidence suggesting that there is a causal link between ZIKV and microcephaly, however, future studies are warranted to solidify this association. To summarize the most recent evidence on this issue and provide perspectives for future studies, we reviewed the literature to identify existing evidence of the causal link between ZIKV infection and microcephaly within research related to the epidemics, laboratory diagnosis, and possible mechanisms.
[Mh] Termos MeSH primário: Feto/virologia
Microcefalia/etiologia
Microcefalia/virologia
Infecção pelo Zika virus/complicações
Infecção pelo Zika virus/fisiopatologia
Zika virus/patogenicidade
[Mh] Termos MeSH secundário: Surtos de Doenças
Feminino
Seres Humanos
Lactente
América Latina/epidemiologia
Microcefalia/epidemiologia
Microcefalia/fisiopatologia
Gravidez
Infecção pelo Zika virus/epidemiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW; RESEARCH SUPPORT, NON-U.S. GOV'T
[Em] Mês de entrada:1707
[Cu] Atualização por classe:171218
[Lr] Data última revisão:
171218
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161025
[St] Status:MEDLINE



página 1 de 963 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde